Hypoxia represses early responses of prostate and renal cancer cells to YM155 independent of HIF-1α and HIF-2α
{{output}}
The imidazolium compound Sepantronium Bromide (YM155) successfully promotes tumor regression in various pre-clinical models but has shown modest responses in human clinical trials. We provide evidence to support that the hypoxic milieu of tumors may limit the ... ...
